ReviewProgress in retinal and eye research2019
Targets of immunomodulation in bacterial endophthalmitis.
Review in Progress in retinal and eye research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 74 citations in OpenAlex.
- Article
- Ocular Abscess Causing Remarkable Eyeball Deformity.Internal medicine (Tokyo, Japan) · 2026Article
- Resolvin D1 requires TLR2-FPR2 crosstalk for inflammation resolution and protection during ocular bacterial infection.Communications biology · 2026Article
- Pathogenic Characterization and Host Immune Response toAnimals : an open access journal from MDPI · 2026Article
- A Tailored Artificial Biocatalyst for Bacterial Endophthalmitis Therapy via Enhanced Ferroptosis-Like Death.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Poly-(L-homoarginine) for the non-invasive treatment of endophthalmitis.Materials today. Bio · 2025Article
- Proteomic profiling reveals immunomodulatory role of IL-33 in ocular bacterial and fungal infections.Infection and immunity · 2025Article
- Metabolomic Profiling of Ocular Fluid Identifies Host Response Factors for Risk Stratification in Bacterial Endophthalmitis.Investigative ophthalmology & visual science · 2025Article
- Myeloid Cell-Specific Deletion of AMPKα1 Worsens Ocular Bacterial Infection by Skewing Macrophage Phenotypes.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Deciphering infectious uveitis etiology: Immune cell profiling in keratic precipitates using in vivo confocal microscopy.Heliyon · 2024Article
- Age-Associated Alterations in the Metabolome of Human Vitreous in Bacterial Endophthalmitis.Investigative ophthalmology & visual science · 2024Article
- The Role of CCL Chemokines in Experimental Staphylococcus aureus Endophthalmitis.Investigative ophthalmology & visual science · 2024Article
- Untargeted and temporal analysis of retinal lipidome in bacterial endophthalmitis.Prostaglandins & other lipid mediators · 2024Review
- Predatory bacteria prevent the proliferation of intraocularMicrobiology (Reading, England) · 2024Article
- Bacteria-Targeting Nanoparticles with ROS-Responsive Antibiotic Release to Eradicate Biofilms and Drug-Resistant Bacteria in Endophthalmitis.International journal of nanomedicine · 2024Article
- The impact of oxygen content onFrontiers in microbiology · 2024Article
- Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications.Frontiers in immunology · 2024Review
- Oral administration of S-nitroso-L-glutathione (GSNO) provides anti-inflammatory and cytoprotective effects during ocular bacterial infections.Cellular and molecular life sciences : CMLS · 2023Article
- Comparative evaluation of 16S rRNA metagenomic sequencing in the diagnosis and understanding of bacterial endophthalmitis.BMJ open ophthalmology · 2023Article
- The Fibro-Inflammatory Response in the Glaucomatous Optic Nerve Head.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Bacterial infection of the posterior segment of the eye (endophthalmitis) leads to a robust host response that often results in irreversible damage to the layers of the retina, significant vision loss, and in some patients, enucleation of the globe. While a great deal of effort has gone into understanding the role of bacterial virulence factors in disease initiation and propagation, it is becoming increasingly clear that the host response to infection plays a major role in causing the damage associated with endophthalmitis. Researchers have identified the host receptors which detect infecting organisms and initiate the cascade of events that result in inflammation. This inflammation may damage nonregenerative tissues of the eye while attempting to clear the infection. Both Gram-positive and Gram-negative bacteria can cause endophthalmitis. These organisms initiate an immune response by activating toll-like receptor (TLR) pathways. Once an inflammatory response is initiated, the expression of immunomodulators, such as proinflammatory chemokines and cytokines, affect the recruitment of PMNs and other inflammatory cells into the eye. We and others have reported that knockout mice that do not express specific inflammatory pathways and molecules have an attenuated response to infection and retain significant retinal function. These findings suggest that host immune mediators are important components of the response to infections in the posterior segment of the eye, and the timing and level of their production may be related to the severity of the damage and the ultimate visual outcome. If that is the case, a better understanding of the complex and often redundant role of these pathways and inflammatory mediators may identify host molecules as potential anti-inflammatory therapeutic targets. This review highlights potential anti-inflammatory targets during acute inflammation in endophthalmitis, compares and contrasts those with findings in other models of ocular inflammation, and translates current immunomodulatory strategies for other types of infection and inflammation to this blinding disease. Given the poor visual outcomes seen in patients treated with antibiotics alone or in combination with corticosteroids, immunomodulation in addition to antibiotic therapy might be more effective in preserving vision than current regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.